(Total Views: 658)
Posted On: 02/21/2020 7:26:50 AM
Post# of 154147
The primary endpoint of the approved basket trial is progression-free survival .
A good article about the posibility of this being a primary end-point for trials.
https://clincancerres.aacrjournals.org/content/19/10/2607
I think the 30 patients number is a good move. Not too large so a small company (like CYDY) can lose control of data/centers and take forever on doing it, and not too small so the results cannot be taken as meaningless.
Another big advantage is that we can have a continuous stream of news from the patients wellbeing as the data is being obtained. No surprises one way or another
In any case, we have already at least two patients with much-improved PFS !!!
Great news for Friday morning ...
A good article about the posibility of this being a primary end-point for trials.
https://clincancerres.aacrjournals.org/content/19/10/2607
I think the 30 patients number is a good move. Not too large so a small company (like CYDY) can lose control of data/centers and take forever on doing it, and not too small so the results cannot be taken as meaningless.
Another big advantage is that we can have a continuous stream of news from the patients wellbeing as the data is being obtained. No surprises one way or another
In any case, we have already at least two patients with much-improved PFS !!!
Great news for Friday morning ...
(4)
(0)
